# Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)

> **NCT01146977** · PHASE2 · UNKNOWN · sponsor: **Cooperative Study Group A for Hematology** · enrollment: 43 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** HDAC chemotherapy
- **OTHER:** Autologous HCT

## Key facts

- **NCT ID:** NCT01146977
- **Lead sponsor:** Cooperative Study Group A for Hematology
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2010-01
- **Final completion:** 2015-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2010-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146977, "Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01146977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*